Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Medullary × In Situ Hybridization, Fluorescence × Clear all

Status

Active not recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Leukemia 11 Leukemia, Lymphocytic, Chronic, B-Cell 10 Breast Neoplasms 10 Multiple Myeloma 7 Lymphoma, Mantle-Cell 7 Leukemia, Myeloid, Acute 7 Congenital Abnormalities 7 Precursor Cell Lymphoblastic Leukemia-Lymphoma 6 Lymphoma, Follicular 6 Lymphoma, B-Cell, Marginal Zone 6 Waldenstrom Macroglobulinemia 5 Myeloproliferative Disorders 5 Lymphoma, Non-Hodgkin 5 Lymphoma, Large B-Cell, Diffuse 5 Burkitt Lymphoma 5 Squamous Cell Carcinoma of Head and Neck 4 Lymphoma, Large-Cell, Immunoblastic 4 Lymphoma 4 Lung Neoplasms 4 Leukemia, Myelomonocytic, Chronic 4 Leukemia, Myeloid, Chronic-Phase 4 Head and Neck Neoplasms 4 Colorectal Neoplasms 4 Colonic Neoplasms 4 Central Nervous System Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Sezary Syndrome 3 Myelodysplastic Syndromes 3 Mycosis Fungoides 3 Lymphoma, Large-Cell, Anaplastic 3

Interventions

vandetanib 14 cabozantinib 8 selpercatinib 6 Everolimus 5 Sorafenib 4 Magnetic Resonance Spectroscopy 3 Capecitabine 3 sargramostim 2 pralsetinib 2 lutetium Lu 177 dotatate 2 lenvatinib 2 Trastuzumab 2 Temozolomide 2 Sunitinib 2 Octreotide 2 Gefitinib 2 yeast-CEA vaccine 1 veliparib 1 vatalanib 1 tumor necrosis factor-alpha, CNGRC fusion protein, human 1 tipifarnib 1 temsirolimus 1 tanespimycin 1 sacubitril and valsartan sodium hydrate drug combination 1 ponatinib 1 pentetreotide 1 pembrolizumab 1 pazopanib 1 pasireotide 1 nintedanib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04970134 2024-09-19

MOLTHY

Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Active not recruiting

Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon ⚡